Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18076660 | 0.82 | CA1 (0.44) | ALDH1A1CYP3A4TSHRTDP1CA1 | |
| SCHEMBL146892 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL29066927 | 0.75 | CYP3A4 (0.43) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL27871748 | 0.75 | ALDH1A1 (0.33) | ALDH1A1NQO2 | |
| SCHEMBL18426752 | 0.75 | CA1 (0.39) | ALDH1A1CA1CA2CA9MAPK1 | |
| SCHEMBL159075 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL6624352 | 0.75 | KDM4E (0.45) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL19723645 | 0.75 | CA1 (0.54) | ALDH1A1CYP3A4TSHRTDP1CA1 | |
| SCHEMBL109929 | 0.75 | CYP3A4 (0.43) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL16379755 | 0.73 | TTR (0.48) | ALDH1A1CYP3A4TSHRTDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705296-A1 | HETEROARYLINDOLE INHIBITORS OF APOL-1 | OmniAB, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024242846-A1 | HETEROARYLINDOLE INHIBITORS OF APOL-1 | OMNIAB, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009130434-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130434-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| CN-101437519-A | Indazole compounds | ABBOTT LAB (US) | 2009-05-20 | — | — | CN | disclosed |
| EP-2001480-A2 | INDAZOLE COMPOUNDS | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | ALDH1A1 89/4885CYP3A4 5/4885TSHR 2823/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 2338/4885CYP3A4 57/4885TSHR 1662/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ALDH1A1 2338/4885CYP3A4 57/4885TSHR 1662/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 2338/4885CYP3A4 57/4885TSHR 1662/4885 |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CSNK1E, PACSIN2, CHUK | ALDH1A1 4456/4885CYP3A4 4370/4885TSHR 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.